Insufficient scRNA-seq data for expression of CHST4 at single-cell level.
Insufficient scRNA-seq data for expression of CHST4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 349.41 | 327 / 328 | 87% | 31.37 | 155 / 178 |
liver | 100% | 215.48 | 226 / 226 | 28% | 14.52 | 114 / 406 |
adrenal gland | 98% | 144.86 | 253 / 258 | 20% | 1.10 | 47 / 230 |
lung | 72% | 32.41 | 415 / 578 | 39% | 2.49 | 452 / 1155 |
ovary | 26% | 5.09 | 46 / 180 | 76% | 5.15 | 328 / 430 |
stomach | 33% | 7.39 | 120 / 359 | 38% | 3.24 | 109 / 286 |
breast | 51% | 11.43 | 234 / 459 | 14% | 1.06 | 162 / 1118 |
adipose | 58% | 29.41 | 696 / 1204 | 0% | 0 | 0 / 0 |
intestine | 10% | 1.56 | 93 / 966 | 46% | 6.31 | 243 / 527 |
thymus | 50% | 8.81 | 329 / 653 | 5% | 0.15 | 32 / 605 |
esophagus | 19% | 9.99 | 277 / 1445 | 36% | 3.77 | 66 / 183 |
uterus | 24% | 8.38 | 41 / 170 | 23% | 1.53 | 107 / 459 |
prostate | 44% | 6.96 | 108 / 245 | 0% | 0.01 | 2 / 502 |
kidney | 27% | 4.60 | 24 / 89 | 4% | 0.10 | 38 / 901 |
bladder | 10% | 0.86 | 2 / 21 | 19% | 1.65 | 98 / 504 |
lymph node | 0% | 0 | 0 / 0 | 28% | 0.59 | 8 / 29 |
tonsil | 0% | 0 | 0 / 0 | 24% | 2.33 | 11 / 45 |
peripheral blood | 17% | 16.61 | 159 / 929 | 0% | 0 | 0 / 0 |
spleen | 12% | 1.59 | 29 / 241 | 0% | 0 | 0 / 0 |
heart | 7% | 1.49 | 63 / 861 | 0% | 0 | 0 / 0 |
skin | 1% | 0.15 | 24 / 1809 | 4% | 0.10 | 21 / 472 |
brain | 3% | 0.59 | 87 / 2642 | 2% | 0.04 | 13 / 705 |
blood vessel | 2% | 0.43 | 32 / 1335 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.04 | 3 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006955 | Biological process | immune response |
GO_0005975 | Biological process | carbohydrate metabolic process |
GO_0016266 | Biological process | O-glycan processing |
GO_0006044 | Biological process | N-acetylglucosamine metabolic process |
GO_0006954 | Biological process | inflammatory response |
GO_0007155 | Biological process | cell adhesion |
GO_0006790 | Biological process | sulfur compound metabolic process |
GO_0007267 | Biological process | cell-cell signaling |
GO_0006477 | Biological process | protein sulfation |
GO_1903238 | Biological process | positive regulation of leukocyte tethering or rolling |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0000139 | Cellular component | Golgi membrane |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0001517 | Molecular function | N-acetylglucosamine 6-O-sulfotransferase activity |
Gene name | CHST4 |
Protein name | Carbohydrate sulfotransferase 4 (EC 2.8.2.-) (Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 3) (GST-3) (High endothelial cells N-acetylglucosamine 6-O-sulfotransferase) (HEC-GlcNAc6ST) (L-selectin ligand sulfotransferase) (LSST) (N-acetylglucosamine 6-O-sulfotransferase 2) (GlcNAc6ST-2) (Gn6st-2) |
Synonyms | |
Description | FUNCTION: Sulfotransferase involved in SELL/L-selectin ligand biosynthesis pathway. Catalyzes the transfer of the sulfate group from 3'-phospho-5'-adenylyl sulfate (PAPS) onto the hydroxyl group at C-6 position of the non-reducing N-acetylglucosamine (GlcNAc) residue within O-linked mucin-type glycans. Contributes to generate sialyl 6-sulfo Lewis X determinant (also known as MECA-79 epitope) for SELL recognition, a prerequisite for continuous lymphocyte homing into peripheral lymph nodes and antigen immune surveillance . Transfers the sulfate group primarily on core 2 GlcNAcbeta1-6(Galbeta1-3)GalNAcalphaSer/Thr and extended core 1 GlcNAcbeta1-3Galbeta1-3GalNAcalphaSer/Thr based O-linked glycans on CD34 and GLYCAM1 peripheral node addressins (PNAds) expressed on the lumenal side of high endothelial venules (HEVs) . The recognition of PNAds by SELL initiates a multistep process comprising tethering and rolling of blood lymphocytes on HEVs against the blood flow, followed by chemokine signaling, integrin-mediated lymphocyte adhesion onto endothelial cells and lymphocyte transendothelial migration. Modulates rolling velocity and differential T and B lymphocyte recruitment into peripheral lymph nodes, with a major role in B lymphocyte homing. Might be redundant in sulfation of MADCAM1 and lymphocyte trafficking to mesenteric lymph nodes (By similarity). Can also sulfonate core 3 GlcNAcbeta1-3GalNAc-R based glycans as well as GlcNAcbeta1-3Galbeta1-Glc, GlcNAcbeta1-6ManOMe and GlcNAcbeta1-2Man oligosaccharides, which might be ectopically expressed during tumorigenesis . . |
Accessions | ENST00000539698.4 ENST00000338482.5 Q8NCG5 |